Small Bowel Adenocarcinoma.
Fiche publication
Date publication
septembre 2016
Journal
Gastroenterology clinics of North America
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain
Tous les auteurs :
Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR
Lien Pubmed
Résumé
Small bowel adenocarcinomas (SBAs) are rare tumors, but their incidence is increasing. The most common primary location is the duodenum. Even though SBAs are more often sporadic, some diseases are risk factors. Early diagnosis of small bowel adenocarcinoma remains difficult, despite significant radiologic and endoscopic progress. After R0 surgical resection, the main prognostic factor is lymph node invasion. An international randomized trial (BALLAD [Benefit of Adjuvant Chemotherapy For Small Bowel Adenocarcinoma] study) will evaluate the benefit of adjuvant chemotherapy. For metastatic disease, retrospectives studies suggest that platinum-based chemotherapy is the most effective treatment. Phase II studies are ongoing to evaluate targeted therapy in metastatic SBA.
Mots clés
Adenocarcinoma, diagnosis, Adenomatous Polyposis Coli Protein, genetics, Capsule Endoscopy, Chemotherapy, Adjuvant, Digestive System Surgical Procedures, Double-Balloon Enteroscopy, Duodenal Neoplasms, diagnosis, Humans, Intestinal Neoplasms, diagnosis, Intestine, Small, Mutation, Phenotype, Prognosis, Proto-Oncogene Proteins p21(ras), genetics, Receptor, ErbB-2, genetics, Risk Factors, Tomography, X-Ray Computed, Tumor Suppressor Protein p53, metabolism, beta Catenin, metabolism
Référence
Gastroenterol. Clin. North Am.. 2016 09;45(3):447-57